ArticlePLoS neglected tropical diseases2025
FC-duplex IgG1 (HTLV-1/2): Qualifying the flow cytometry IgG1 duplex assay for differential diagnosis of HTLV-1 and HTLV-2 infections.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Human T-lymphotropic virus (HTLV) infection has been implicated in a broad spectrum of clinical conditions, encompassing both neoplastic and inflammatory-degenerative disorders, associated with relevant immunological dysfunctions. Given the distinct epidemiological profiles and clinical manifestations associated with HTLV-1 and HTLV-2 infections, establishing an accurate differential diagnosis is of critical importance. The serological/molecular approaches currently available for differential diagnosis are expensive, time-consuming, and require multiple complementary assays, and still lead to inconclusive results. In this context, the development of a single-platform assay referred to as FC-Duplex IgG1 (HTLV-1/2) assay represented a valuable advance for the differential diagnosis of HTLV infections in clinical settings, while counseling HTLV-seropositive patients and/or conducting seroepidemiological surveys. The present study aimed at qualifying the FC-Duplex IgG1 (HTLV-1/2) kit prototype for differential serodiagnosis of HTLV-1 and HTLV-2 infections. A biorepository library, composed of serum samples from four HTLV reference centers (HTLV-1(+)/n = 225; HTLV-2(+)/n = 80 and HTLV1/2(-)/n = 55), was tested for anti-HTLV-1 and anti-HTLV-2 IgG1 reactivity using three classification criteria. Discriminant performance analysis supported the high accuracy of FC-Duplex IgG1 (HTLV-1/2) with elevated proportion of correct classification according to PCR & Western Blot reference standards (Criterion 3 = 89%; Criterion 2 = 90% and Criterion 1 = 99%). Decision tree accuracy and Leave One Out Cross-Validation re-enforced the robustness, confirming the minimal overfitting of our findings. Kappa agreement indices further confirmed the substantial to near perfect agreement of FC-Duplex IgG1 (HTLV-1/2) with reference standard methods (Criterion 3 = 0.72; Criterion 2 = 0.75 and Criterion 1 = 0.97). Altogether, these findings qualified the FC-Duplex IgG1 (HTLV-1/2) assay for differential diagnosis of HTLV-1/2 infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.